F F Chen1, D Zhang, Y L Wang, B Xiong. 1. Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, 430071 Wuhan, China.
Abstract
AIMS: Video-assisted thoracoscopic surgery (VATS) lobectomy for early lung cancer has been shown to be technically feasible. Weather VATS lobectomy has equivalent or better clinical effect compared with open lobectomy for early lung cancer patients remains controversial. The purpose is to assess the value of VATS compared with thoracotomy for stage Ⅰ non-small cell lung cancer (NSCLC) by meta-analysis. METHODS: We searched databases of EMBASE, PubMed, and ScienceDirect for relevant articles published between January 1990 and January 2013. Eligible studies were randomized controlled trials (RCTs) or comparative studies of VATS lobectomy and open lobectomy for clinical stage Ⅰ NSCLC. Data on operation time, intra-operative blood loss, length of chest tube drainage and hospital stay, complications incidence and 5 year survival rate were meta-analyzed using Review Manager 5.0. RESULTS: 20 studies with 3457 clinical stage Ⅰ NSCLC patients were included. There was no difference in operation time between the two groups (P = 0.14), but distinct advantages in terms of intra-operative blood loss, chest drainage time, hospital stay and complication incidence were found in the VATS group (P < 0.01). Moreover, the 5 year survival rate of VATS group was significantly higher than thoracotomy group (OR 1.82, 95% CI, 1.43-2.31, P < 0.01). CONCLUSION: Compared with thoracotomy group, VATS achieved better surgical and oncological outcomes and was a more favorable treatment for stage Ⅰ NSCLC patients.
AIMS: Video-assisted thoracoscopic surgery (VATS) lobectomy for early lung cancer has been shown to be technically feasible. Weather VATS lobectomy has equivalent or better clinical effect compared with open lobectomy for early lung cancerpatients remains controversial. The purpose is to assess the value of VATS compared with thoracotomy for stage Ⅰ non-small cell lung cancer (NSCLC) by meta-analysis. METHODS: We searched databases of EMBASE, PubMed, and ScienceDirect for relevant articles published between January 1990 and January 2013. Eligible studies were randomized controlled trials (RCTs) or comparative studies of VATS lobectomy and open lobectomy for clinical stage Ⅰ NSCLC. Data on operation time, intra-operative blood loss, length of chest tube drainage and hospital stay, complications incidence and 5 year survival rate were meta-analyzed using Review Manager 5.0. RESULTS: 20 studies with 3457 clinical stage Ⅰ NSCLCpatients were included. There was no difference in operation time between the two groups (P = 0.14), but distinct advantages in terms of intra-operative blood loss, chest drainage time, hospital stay and complication incidence were found in the VATS group (P < 0.01). Moreover, the 5 year survival rate of VATS group was significantly higher than thoracotomy group (OR 1.82, 95% CI, 1.43-2.31, P < 0.01). CONCLUSION: Compared with thoracotomy group, VATS achieved better surgical and oncological outcomes and was a more favorable treatment for stage Ⅰ NSCLCpatients.
Authors: Chang Li; Chun Xu; Haitao Ma; Bin Ni; Jun Chen; Tengfei Chen; Hongtao Zhang; Jun Zhao Journal: Thorac Cancer Date: 2014-04-22 Impact factor: 3.500
Authors: Paul J Scheel; Traves D Crabtree; Jennifer M Bell; Christine Frederiksen; Stephen R Broderick; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: J Thorac Cardiovasc Surg Date: 2014-12-20 Impact factor: 5.209
Authors: Teodora-Cristiana Dumitra; Juan-Carlos Molina; Jack Mouhanna; Ioana Nicolau; Stephane Renaud; Ludovic Aubin; Aya Siblini; David Mulder; Lorenzo Ferri; Jonathan Spicer Journal: Can J Surg Date: 2020-07-31 Impact factor: 2.089